Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARDX NASDAQ:AUPH NASDAQ:CRVS NASDAQ:ELVN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARDXArdelyx$4.57-0.8%$3.90$3.21▼$7.18$1.09B0.64.43 million shs1.49 million shsAUPHAurinia Pharmaceuticals$8.96+1.2%$8.12$5.20▼$10.67$1.21B1.161.40 million shs1.11 million shsCRVSCorvus Pharmaceuticals$4.23-0.6%$3.94$2.10▼$10.00$288.02M0.58860,134 shs197,405 shsELVNEnliven Therapeutics$22.91+6.8%$19.93$13.30▼$30.03$1.12B0.83371,584 shs507,088 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARDXArdelyx+2.22%0.00%+25.68%-4.56%-25.93%AUPHAurinia Pharmaceuticals-1.56%+5.48%+8.72%+14.02%+52.59%CRVSCorvus Pharmaceuticals+1.92%+1.67%-0.23%+31.17%+82.40%ELVNEnliven Therapeutics-0.88%-0.56%-7.06%+29.82%-12.94%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARDXArdelyx4.0982 of 5 stars3.51.00.04.42.62.50.6AUPHAurinia Pharmaceuticals3.1754 of 5 stars3.52.00.00.03.40.81.9CRVSCorvus Pharmaceuticals2.8664 of 5 stars3.51.00.00.03.33.30.6ELVNEnliven Therapeutics2.8145 of 5 stars3.52.00.00.02.54.20.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARDXArdelyx 3.00Buy$10.89138.53% UpsideAUPHAurinia Pharmaceuticals 3.00Buy$11.5028.42% UpsideCRVSCorvus Pharmaceuticals 3.00Buy$15.00255.03% UpsideELVNEnliven Therapeutics 3.00Buy$41.2079.83% UpsideCurrent Analyst Ratings BreakdownLatest CRVS, AUPH, ARDX, and ELVN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/2/2025ELVNEnliven TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$40.00 ➝ $48.006/18/2025ARDXArdelyxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$10.006/16/2025ELVNEnliven TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$40.00 ➝ $52.006/16/2025ELVNEnliven TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$37.005/20/2025CRVSCorvus PharmaceuticalsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOutperform ➝ Outperform$12.00 ➝ $11.005/16/2025ELVNEnliven TherapeuticsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$36.00 ➝ $27.005/15/2025ELVNEnliven TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$39.00 ➝ $40.005/9/2025CRVSCorvus PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$15.00 ➝ $17.005/2/2025ARDXArdelyxCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $10.005/2/2025ARDXArdelyxRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Outperform$11.00(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARDXArdelyx$333.61M3.27N/AN/A$0.73 per share6.25AUPHAurinia Pharmaceuticals$235.13M5.15$0.31 per share29.15$2.68 per share3.34CRVSCorvus PharmaceuticalsN/AN/AN/AN/A$0.51 per shareN/AELVNEnliven TherapeuticsN/AN/AN/AN/A$6.34 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARDXArdelyx-$39.14M-$0.22N/A14.73N/A-14.86%-34.45%-13.81%7/30/2025 (Estimated)AUPHAurinia Pharmaceuticals$5.75M$0.2831.9815.99N/A16.11%14.27%9.93%7/30/2025 (Estimated)CRVSCorvus Pharmaceuticals-$62.29M-$0.98N/AN/AN/AN/A-24.04%-13.90%8/5/2025 (Estimated)ELVNEnliven Therapeutics-$89.02M-$1.92N/AN/AN/AN/A-31.84%-30.09%8/12/2025 (Estimated)Latest CRVS, AUPH, ARDX, and ELVN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025ELVNEnliven Therapeutics-$0.54N/AN/AN/AN/AN/A8/7/2025Q2 2025ARDXArdelyx-$0.12N/AN/AN/AN/AN/A8/7/2025Q2 2025AUPHAurinia Pharmaceuticals$0.18N/AN/AN/A$64.27 millionN/A8/5/2025Q2 2025CRVSCorvus Pharmaceuticals-$0.13N/AN/AN/AN/AN/A5/14/2025Q1 2025ELVNEnliven Therapeutics-$0.51-$0.57-$0.06-$0.57N/AN/A5/12/2025Q1 2025AUPHAurinia Pharmaceuticals$0.08$0.16+$0.08$0.16$61.06 million$62.47 million5/8/2025Q1 2025CRVSCorvus Pharmaceuticals-$0.13-$0.13N/A-$0.13N/AN/A5/1/2025Q1 2025ARDXArdelyx-$0.10-$0.17-$0.07-$0.17$79.40 million$74.11 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARDXArdelyxN/AN/AN/AN/AN/AAUPHAurinia PharmaceuticalsN/AN/AN/AN/AN/ACRVSCorvus PharmaceuticalsN/AN/AN/AN/AN/AELVNEnliven TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARDXArdelyx1.044.123.81AUPHAurinia Pharmaceuticals0.165.935.26CRVSCorvus PharmaceuticalsN/A4.904.90ELVNEnliven TherapeuticsN/A21.0721.06Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARDXArdelyx58.92%AUPHAurinia Pharmaceuticals36.83%CRVSCorvus Pharmaceuticals46.64%ELVNEnliven Therapeutics95.08%Insider OwnershipCompanyInsider OwnershipARDXArdelyx4.80%AUPHAurinia Pharmaceuticals12.20%CRVSCorvus Pharmaceuticals28.50%ELVNEnliven Therapeutics25.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARDXArdelyx90239.26 million227.77 millionOptionableAUPHAurinia Pharmaceuticals300135.10 million118.62 millionOptionableCRVSCorvus Pharmaceuticals3068.17 million48.74 millionOptionableELVNEnliven Therapeutics5049.07 million36.36 millionOptionableCRVS, AUPH, ARDX, and ELVN HeadlinesRecent News About These CompaniesEnliven Therapeutics (NASDAQ:ELVN) Shares Down 5.7% - Here's What HappenedJuly 15 at 4:23 PM | marketbeat.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells $22,660.00 in StockJuly 15 at 4:42 AM | insidertrades.comBenjamin Hohl Sells 1,000 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) StockJuly 14 at 7:19 PM | marketbeat.comEnliven Therapeutics Breaks Above 200-Day Moving Average - NasdaqJuly 12, 2025 | nasdaq.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) Receives Average Rating of "Buy" from BrokeragesJuly 11, 2025 | americanbankingnews.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) Receives Average Recommendation of "Buy" from BrokeragesJuly 11, 2025 | marketbeat.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) COO Anish Patel Sells 6,667 SharesJuly 9, 2025 | marketbeat.comEnliven Therapeutics (NASDAQ:ELVN) Trading 5.4% Higher - What's Next?July 9, 2025 | marketbeat.comQ2 EPS Forecast for Enliven Therapeutics Boosted by AnalystJuly 4, 2025 | marketbeat.comEnliven Therapeutics (NASDAQ:ELVN) Shares Up 7.9% Following Analyst UpgradeJuly 2, 2025 | marketbeat.comEnliven Therapeutics (NASDAQ:ELVN) Stock Price Expected to Rise, HC Wainwright Analyst SaysJuly 2, 2025 | marketbeat.comBenjamin Hohl Sells 3,250 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) StockJuly 2, 2025 | insidertrades.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl Sells 3,250 SharesJuly 1, 2025 | marketbeat.comEnliven Therapeutics’ Promising CML Study: A Potential Game-Changer?June 30, 2025 | tipranks.comInsider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) Insider Sells 12,500 Shares of StockJune 24, 2025 | marketbeat.comEnliven Short Interest Falls To 14-Month Low After Leukemia Trial Data, Goldman Initiates With ‘Buy’June 23, 2025 | msn.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Sells $277,250.00 in StockJune 18, 2025 | marketbeat.comGoldman Sachs initiates Enliven Therapeutics stock with Buy ratingJune 17, 2025 | investing.comEnliven grosses $230M from stock saleJune 17, 2025 | bizwest.comBEnliven Therapeutics, Inc. (ELVN) Backed by Goldman Sachs After Strong Trial DataJune 17, 2025 | msn.comEnliven Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional SharesJune 16, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCRVS, AUPH, ARDX, and ELVN Company DescriptionsArdelyx NASDAQ:ARDX$4.57 -0.04 (-0.76%) As of 02:55 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.Aurinia Pharmaceuticals NASDAQ:AUPH$8.96 +0.11 (+1.19%) As of 02:55 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.Corvus Pharmaceuticals NASDAQ:CRVS$4.22 -0.03 (-0.59%) As of 02:55 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.Enliven Therapeutics NASDAQ:ELVN$22.91 +1.45 (+6.76%) As of 02:55 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is Amazon Really the Best Forever Stock for Your Portfolio? Qualcomm: Undervalued Chip Stock in Breakout Uptrend Broadcom’s Takes on NVIDIA: Why Tomahawk Ultra Could Boost Shares CrowdStrike Bulls Beware: This Trade May Be Getting Crowded AMD Just Triggered a Signal Traders Can’t Ignore JNJ’s Stock Price Is Back in Rally Mode—The Time to Buy Is Now Citigroup Earnings Could Signal What’s Next for Markets This ASML Dip Could Be Gone Before You Know It—Don’t Miss Out Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
